LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Kodu・Aktsiate loetelu・MacroGenics Inc

MacroGenics Inc

Suletud

SektorTervishoid

4.52 6.1

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.22

Max

4.63

Põhinäitajad
By Trading Economics
Sissetulek	-23M -37M
Müük	-20M 21M
Aktsiakasum	-0.58
Kasumimarginaal	-177.011
Töötajad	293
EBITDA	-17M -32M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+49.29% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. aug 2026

Turustatistika
By TradingEconomics
Turukapital	89M 276M
Eelmine avamishind	-1.58
Eelmine sulgemishind	4.52

Uudiste sentiment

By Acuity

29%

71%

66 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

1.47 / 1.64 Toetus ja vastupanu

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. mai 2026, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21. mai 2026, 16:49 UTC

Tulu

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21. mai 2026, 16:26 UTC

Suurimad hinnamuutused turgudel

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21. mai 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21. mai 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21. mai 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21. mai 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21. mai 2026, 22:33 UTC

Omandamised, ülevõtmised, äriostud

Conduent to Sell Public Transit Business to Modaxo for $164M

21. mai 2026, 21:53 UTC

Tulu

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21. mai 2026, 21:02 UTC

Tulu

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21. mai 2026, 20:55 UTC

Tulu

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21. mai 2026, 20:30 UTC

Kuumad aktsiad

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21. mai 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. mai 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21. mai 2026, 20:20 UTC

Tulu

Webull 1Q Adj EPS 3c >BULL

21. mai 2026, 20:20 UTC

Tulu

Webull 1Q Rev $159.9M >BULL

21. mai 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21. mai 2026, 20:18 UTC

Tulu

Webull 1Q Loss/Shr 4c

21. mai 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21. mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21. mai 2026, 18:58 UTC

Tulu

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21. mai 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21. mai 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21. mai 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21. mai 2026, 17:01 UTC

Tulu

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21. mai 2026, 16:20 UTC

Market Talk

Tulu

Stellantis Targets Distant but Constructive -- Market Talk

21. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

49.29% tõus

12 kuu keskmine prognoos

Keskmine 6.33 USD 49.29%

Kõrge 9 USD

Madal 4 USD

Põhineb 5 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi MacroGenics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.47 / 1.64Toetus ja vastupanu

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

66 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.